Oral GLP-1 Orforglipron Shows 12.4% Weight Loss in Eli Lilly Trial
LLY sits 59% above its 52-week low of $623.78.
Summary
Eli Lilly's oral GLP-1 agonist, orforglipron, demonstrated a significant 12.4% weight loss in overweight adults over 72 weeks in a clinical trial. This strong efficacy for an oral formulation is a material development, especially when compared to recent competitor data showing 10.7% weight loss for an injectable. The company also announced that its approved weight-loss drug, Zepbound, will be offered to employers via GoodRx's 'Employer Direct' platform, enhancing market access. Additionally, Eli Lilly committed $1.68 million to the WHO Foundation for obesity care, though this financial contribution is minor relative to the company's size. The impressive orforglipron data reinforces Eli Lilly's leadership in the rapidly growing obesity treatment market and provides a strong pipeline candidate. Investors will closely monitor the planned Q2 U.S. launch of orforglipron, pending FDA approval.
At the time of this announcement, LLY was trading at $990.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $934.2B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.